Metformin Outperforms Semaglutide for Brain Protection in Network Analysis of Diabetes-AD Pathways | Research

The takeaway

Network pharmacology analysis ranks metformin as the most neuroprotective diabetes therapy for Alzheimer's, while semaglutide shows minimal engagement with core neurodegenerative pathways despite its clinical prominence.

Metformin > semaglutide
Network analysis ranks cheap metformin as the best diabetes drug for AD protection, with expensive semaglutide near the bottom

What the researchers found

Metformin ranked highest for AD protection via AMPK/insulin/adipocytokine pathways. Semaglutide ranked among the least effective, showing minimal engagement with DM2-AD comorbidity network pathways. Insulin/GLP-1 combinations showed effects comparable to metformin.

Why it matters

Despite enormous excitement about semaglutide for AD, this computational analysis suggests metformin may actually be the better diabetes drug for brain protection, redirecting research priorities.

How the study worked

Integrative comparative network pharmacology of 39 diabetes therapies within the DM2-AD pathway-pathway comorbidity network, validated with gene expression data.

What this study cannot tell us

Computational analysis only. Network pharmacology predicts pathway engagement, not clinical outcomes. Rodent gene expression validation may not translate to humans. Does not account for drug concentrations in the brain.

How to read the evidence

Computational network pharmacology validated with gene expression data. Novel methodology but needs clinical outcome validation.

When this study was published

Published in 2025.

The bigger picture

This challenges the narrative that newer, more expensive drugs are always better. For AD prevention in diabetic patients, cheap metformin may outperform costly semaglutide.

Questions still open

Should clinical trials prioritize metformin over semaglutide for AD prevention?
Does metformin's higher AMPK engagement translate to actual neuroprotection in humans?
Could metformin + semaglutide combination provide superior neuroprotection?

Common questions

Is metformin better than Ozempic for preventing Alzheimer's?

This computational analysis suggests yes — metformin engages more of the biological pathways shared between diabetes and Alzheimer's than semaglutide does. But this needs to be confirmed in clinical trials.

Should I take metformin instead of semaglutide?

This is one study using computational methods. Both drugs have different benefits: semaglutide for weight loss and cardiovascular protection, metformin potentially for brain protection. Your doctor can help weigh these factors for your specific situation.

Read the original research

Metformin provides superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer's disease via dual actions.

Communications medicine

View on PubMed ↗Publisher’s paper ↗

Citation

Georgiou, Andrea; Zanos, Panos; Onisiforou, Anna. (2026). Metformin provides superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer's disease via dual actions.. Communications medicine. https://doi.org/10.1038/s43856-026-01471-3